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one of the most challenging objective for clinical cytometry in prospective multicenter 
immunomonitoring trials is to compare frequencies, absolute numbers of leukocyte populations and 
further the mean fluorescence intensities of cell markers, especially when the data are generated from 
different instruments. Here, we describe an innovative standardization workflow to compare all data 
to carry out any large-scale, prospective multicentric flow cytometry analysis whatever the duration, 
the number or type of instruments required for the realization of such projects.
One of the challenges not yet fully resolved for clinical  cytometry1 is to compare, in prospective multicenter 
immunomonitoring trials, the frequencies and absolute values of various leukocyte populations, especially if the 
data are generated from different instruments and from different companies. The problem is even more difficult 
when it comes to comparing the expression of the  markers2 on freshly collected sample to avoid alteration of 
expression following freezing  processes3. If the fluorescence variations between different antibody lots remain a 
major problem, the divergent results can be seen as a result of inappropriate gating strategies between the  centers4 
or because of imperfect fluorescence  compensation5,6.
Recently, several studies have sought to move this issue forward without being able to meet all the crite-
ria. Some have chosen to use equipment mainly from the same  manufacturer7,8, others have preferred frozen 
 samples3,9 or have resigned themselves to not doing prospective  studies10, while others have carried out inter-
instrument comparability studies but on few  samples11.
As part of the IMI PRECISESADS study project, a multicenter analysis, using eleven different instruments 
(Navios, Gallios from Beckman Coulter, Canto II, Fortessa, Verse, Aria from BD Biosciences), prospectively 
on blood freshly collected from 2,559 individuals over a period of 4 years, was required. The objective was to 
compare the distribution (frequencies and absolute values) of leukocyte populations and the mean fluorescence 
intensities (MFIs) of the markers of the studied populations in order to establish a new classification of autoim-
mune diseases in relation to all the "omic" collection of data. We have preliminarily developed and published a 
standard operating procedure (SOP) for the standardization of all instruments based on VersaComp Capture 
beads (Beckman Coulter) for inter-center harmonization. The objective was to establish the settings of each 
instrument leading to the generation of similar MFIs when acquiring identical samples. A second SOP was also 
developed using 8 peak beads (Beckman Coulter) for the intra-center daily QC to preserve intra-instrument 
stability over the project period. Overall, these different SOPs were followed by all centers with the aim of 
obtaining inter-instrument coefficients of variation (CVs) of less than 5%12. The relevance of this approach was 
demonstrated by an analysis of the same sample of control blood which highlighted a similar sensitivity of all 
devices in terms of frequencies of populations studied but also in terms of MFI markers  studied12.
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Harmonization of the instruments
The effective harmonization of the instruments through this procedure (Fig. 1, step 1) enables the realization 
of the large-scale multicentric phenotypic analyzes and assumes the stability of the 11 instruments throughout 
the duration of the study. Immunomonitoring of the individuals included in the PRECISESADS study was per-
formed using 2 DuraClone antibody panels (Beckman Coulter) dedicated to the analysis of various populations 
of leukocytes and mononuclear cells in the peripheral blood (Supplementary Table 1). Despite the preliminary 
precautions taken  upstream12, the development of a supplementary standardization was necessary to harmonize 
the flow cytometry data. Different steps have been identified for this procedure and are described in the current 
manuscript.
intra‑center normalization
Initially, a first R script was developed to normalize the results over the 4-year period for each single center based 
on the targets of the initial harmonization in order to correct variations potentially observed in the daily QC 
(Supplementary Document 1). The different steps are: 1. Loading of the packages flowCore, flowStats,flowViz, 
ggcyt; 2. Function to revise channel name position and standard names when necessary; 3. Function to extract 
the MFI of the 8 peak beads files with identification of Beckman Coulter and BD Biosciences files, identifica-
tion of files containing debris; 4. Function to define the alpha and beta transformation parameters that will be 
used to normalize the FCS files; 5. Application of the normalization function using a linear regression with the 
determined alpha and beta parameters and using as a reference the MFI of the 8 peak beads obtained during 
Figure 1.  Workflow of the standardization procedure for the harmonization of flow cytometry data in 
multicentric prospective studies. Flow cytometers are firstly harmonized using VersaComp capture beads to 
achieve the same reference for all instruments (step 1). For the acquisition of blood samples, 8 peak beads are 
used as daily quality control. A R script allows the normalization of the data for each instrument to the reference 
during the period of inclusions (step 2). The compensation of all flow cytometry files are verified and adjusted 
to minimize disparities in the data file preparation (step 3). Frequencies of the populations of interest and the 
mean fluorescence intensities of the cell surface markers are automatically collected from all flow cytometry 
files by automaton having learned the gating strategy through machine learning (step 4). The mean fluorescence 
intensities of the cell surface markers are corrected by a Python script to adjust the median values and eliminate 
antibody batches variations in each instrument (step 5). The mean fluorescence intensities are finally corrected 
by an additional python script to correct the variations of the median values between the instruments (step 6).
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the initial calibration procedure for the harmonization of the instruments; 6. Verification of the effect in all 
channels. In order to validate this script, we performed an additional experiment. We voluntarily modified the 
PMTs of a Navios to provoke a measurement variation of the MFIs of the order of 10 to 15% on the 8 peak beads 
(Supplementary Figure 1a and Supplementary Table 2). As a result, these changes were made in the MFIs of the 
membrane markers studied during the acquisition of a blood test sample with DuraClone Panel 1 (Supplementary 
Figure 1b and Supplementary Table 3). The application of the R script on the LMD files of the 8 peak beads makes 
its MFI correspond to those obtained without modification of the PMTs, with coefficients of variation lower 
than 2.5% (Supplementary Figure 1c and Supplementary Table 2). Executed on the LMD files of the blood test 
sample stained with DuraClone Panel 1, the script also allowed MFIs of the membrane markers corresponding 
to the MFIs obtained without PMT modification, with coefficients of variation of less than 5% (Supplementary 
Figure 1d and Supplementary Table 3). Thus, this R script makes it possible to standardize the results generated 
by the machine (Fig. 1, step 2) and ensures the stability of its data throughout the duration of the project. This 
standardization R script also enables the comparability of the results between the centers, as demonstrated by 
the analysis of the immunomonitoring of the same blood control stained with the DuraClone panel 1, carried 
out after the 4 years. The results show frequency variation coefficients measured between centers ranging from 
2.3% for neutrophils to 17.7% for monocytes, and MFI variation coefficients ranging from 10.9% for the CD3 
molecule to 30.9% for the CD15 molecule (Supplementary Figure 2), confirming the stability of all instrument 
mirroring, performed as a prerequisite before starting the  inclusions12, over the entire study  period12.
“Manual” compensation of the flow cytometry data files
The inclusion of the study’s 2,559 individuals was done along the way during the 4 years of the PRECISESADS 
project between December 2014 and December 2018. All FCS and LMD files from the acquisition of samples 
labeled with DuraClone Panel 1 and DuraClone Panel 2 were standardized with the R script. Then, the stand-
ardized file compensation matrices were verified and adjusted when necessary. This step was completed by the 
same single operator using  Kaluza® software (Beckman Coulter) to minimize file preparation variations (Fig. 1, 
step 3). Values at the beginning (December 2014) and at the end of the inclusions (December 2018) have been 
compared and found statistically reproducible (not shown).
Automated gating of the compensated files
Being extremely time-consuming, the “manual” compensation adjustments were followed by a procedure dedi-
cated to the automated (algorithm based) gating of the FCS files, in order to gather information on frequency 
and absolute number of the cell populations as well as their MFI for the studied markers. Several automated 
gating algorithms have been able to achieve similar results to the centralized manual gating analysis for public 
datasets and have shown the advantages of consistency and  reproducibility13. There are a number of software 
packages available for automatic analysis by multiple algorithms such as dimensionality  reduction14, mixture 
model-based  clustering15, artificial neural  network16, density based  clustering17… Approximately, there are two 
broad categories of automated flow cytometry data analysis approaches. The supervised methods which are 
suitable for mimicking manual gating process for predetermined cell populations and the unsupervised strate-
gies which can identify cell populations with minimal user input, and are notably appropriate for biomarker 
 discovery18,19. For this current study, in order to address the need of an efficient, consistent and robust analysis 
of large scale, multi-parameter flow cytometry datasets from multiple immunomonitoring panels in 11 dif-
ferent centers, we have developed, validated and applied robust and reproducible automated pipelines that 
replicates manual analysis. The automation of gating has been built using a supervised Machine Learning based 
approach using training datasets gated manually. Some unique approaches have been adopted to leverage data 
pre-processing, feature engineering, transfer learning and data augmentation to overcome the major challenges 
encountered in building predictive models for cytometry data automated  gating20. This automation requires a 
two steps workflow. A first step customized for each instrument due to potential strong differences in signal for 
the Forward Scatter and Side Scatter (FS / SS) measures accross cytometers (Supplementary Figure 3a and 3b). A 
second non instrument specific step, for gating remaining populations of interest (Supplementary Figure 3c and 
3d). In order to validate the Machine Learning based algorithms for panel 1 and panel 2 (these algorithms are 
hereafter name automatons), we carried out additional intermediate evaluations. We compared the results of the 
automatons with a traditional "manual" analysis performed with the  Kaluza® software, on 300 patients distributed 
throughout the 11 centers. The comparison of the results shows a very good correlation of the data of frequen-
cies, absolute values and the MFIs (Supplementary Figure 4a–c), making it possible to validate the efficiency of 
the automatons (Fig. 1, step 4). The flow cytometry data (frequencies, absolute values, and MFIs) of the 2,559 
individuals included throughout the 4 years of the study are being extracted automatically by the automatons. A 
principal component analysis (PCA) of these data shows homogeneity of results between centers on frequencies 
(Fig. 2a) but disparities between centers on MFIs (Fig. 2b). What was not observed in analyses of a small number 
of samples  (reference12 and Supplementary Figure 2) has been unveiled with the data from the whole cohort.
intra‑center correction of the data
We, therefore, sought which parameter(s) could be responsible for these "center effects" despite the initial har-
monization of the 11 cytometers and the intra-center normalization of each instrument to circumvent these 
dispersions.
First, the monoclonal antibodies chosen for immunomonitoring are used in DuraClone (Beckman Coulter) 
format. This dried antibody formulation provides stability over time, ease of storage, and avoids pipetting errors 
during sample  preparation21. However, three different lots were used during the 4 years of the study. The MFI 
analysis of each panel 1 (Supplementary Figure 5a–d) and panel 2 (Supplementary Figure 5e–g) markers shows 
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variations in batch changes. Therefore, we elaborated a new script under Python to correct the data between 
batches for each of the 11 instruments including also the variations observed after the 7 calibration  procedures12 
repeated during the 4-year inclusion (see the “Methods” section, and Supplementary Document 2). The different 
steps are: 1. Importation of the usefull modules (os.path, glob, os, matplotlib.pyplot, matplotlib.cbook, numpy, 
pandas, csv, re); 2. Extraction of all the data from the FCS files of a patient ID with search of the acquisition 
dates of the patient ID; 3. Determination of the coefficient for the correction of the batch effect; 4. Computation 
of the coefficient for each batch and application to the MFI of each channel and saving in a new csv file. Briefly, 
a coefficient for each batch is calculated by dividing the MFI of all samples of the first batch by the MFI of all 
samples of each subsequent batch. Then the MFI of each sample is corrected using these coefficients. Based on 
the alignment of the median values of the different batches with those of the first batch used for each center 
(Fig. 1, step 5), the variations of the MFIs over time for each of the markers studied disappeared after application 
of the Python script (Supplementary Figure 5a–g). Nevertheless, despite this correction, the PCA evaluation of 
the distribution of MFIs between instruments showed a persistent "center effect" (Fig. 2c).
inter‑center correction of the data
Intrinsic variations in the optical bench of each instrument remained and lead to measurement disparities in 
MFIs that are dependent on the target of the antibodies used and the associated  fluorochromes8. Assuming that 
the number of individuals included is different from one center to another (Supplementary Figure 6a) but that all 
centers included all the variety of patients (Supplementary Figure 6b) and that the inclusions of the type of indi-
viduals were heterogeneous throughout the 4-year period in all centers (Supplementary Figure 6c), the medians 
of the MFIs on all measures must be equivalent regardless of the center. We therefore developed an additional 
Python script (Supplementary Document 3) to correct the medians of the MFIs of each marker between all the 
instruments (Fig. 1, step 6), using the same Navios cytometer as a reference for all other machines throughout the 
 project12. The different steps are: 1. Importation of the usefull packages (os.path, glob, os, numpy, re, subprocess); 
2. Extraction of the coefficient for the different cytometers used by each center; 3. Computation of the coefficient 
of each instrument and application of each coefficient to the MFI of all channels saved in a new csv file. Briefly, 
a coefficient for each channel is calculated by dividing the MFI of all samples of the reference center by the MFI 
of all samples of all subsequent center. Then the MFI of each sample is corrected using these coefficients. After 
applying this script, the median values of each marker became insignificantly different regardless of the instru-
ment with which the measurements were made (Supplementary Figure 7a,b). A new PCA showed homogeneous 
distribution of MFIs for all the markers studied in panel 1 as well as in panel 2 (Fig. 2d). Yet, individual varia-
tions specific of each patient are still maintained. As an example, the CD19 MFI variations observed between 
Figure 2.  Evolution of principal component analysis during the workflow of the standardization procedure 
of flow cytometry data in multicentric prospective studies. Peripheral blood of 2,559 individuals was labeled 
with the dry panel 1 and panel 2 antibody formulations and then analyzed by flow cytometry using 11 different, 
previously harmonized instruments. The data of each instrument was then standardized by the R script. 
The frequencies of the leukocyte populations (panel 1) and mononuclear cells (panel 2) (a) and the mean 
fluorescence intensities of the cell surface markers (b) were collected from all flow cytometry files by automaton 
having learned the gating strategy through machine learning and were analyzed by principal component 
analysis (PCA). The mean fluorescence intensities of the cell surface markers were corrected by a Python script 
to adjust the median values and eliminate antibody batches variations in each instrument, before being analyzed 
by PCA (c). The mean fluorescence intensities were finally corrected by an additional Python script to eliminate 
the variations of the median values between the instruments, before being analyzed by PCA (d).
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diseases in all centers persist after application of the script pipeline (Supplementary Figure 7c). Importantly, this 
indicate that the harmonization procedure, while correcting the instrument differences, preserve the biological 
differences between individuals.
Finally, the implementation of the workflow described in Fig. 1 made it possible to compare all the data of 
frequencies, absolute values and MFIs resulting from the data generated by the immunomonitoring of 2,559 
individuals included over a period of 4 years by 11 different flow cytometers. Biostatistical analyzes including 
these flow cytometry data with the set of "omic" data collected as part of the PRECISESADS project are now 
possible. More broadly, with all the validity required to follow the elaborated standardization procedures, this 
new workflow opens the possibility of carrying out any large-scale, prospective multicentric flow cytometry 
analysis whatever the duration, number and type of instruments required for the realization of such projects.
Methods
Participant recruitment. The PRECISESADS study is a European multi center, non-randomized, and 
observational clinical study with recruitment performed between December 2014 and December 2018 at 19 
institutions in 9 countries (Austria, Belgium, France, Germany, Hungary, Italy, Portugal, Spain and Switzerland). 
The study had two types of patient recruitment that included a cross-sectional study and an inception prospec-
tive study with patients followed at two time points, registered with number NCT02890121 and NCT02890134 
in ClinicalTrials.gov, respectively. The target number of included patients affected by systemic autoimmune 
diseases was 2005 (around 400 by disease or group of diseases: rheumatoid arthritis, scleroderma or systemic 
sclerosis, primary Sjögren’s syndrome, systemic lupus erythematosus, and primary antiphospholipid syndrome, 
mixed connective tissue disease and undifferentiated connective tissue disease) and 554 healthy controls. An 
ethical protocol was prepared, reached consensus across all partners, academic and industrial, translated into all 
participant’s languages and approved by each of the local ethical committees of the clinical recruitment centers, 
and all experimental protocols were approved by each of the local committees:
• Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore 
Policlinico di Milano, Comitato Etico Italy.
• Centre Hospitalier Universitaire de Brest, Hospital de la Cavale Blanche, Avenue Tanguy Prigent 29,609, 
Brest, France. Comite de Protection des Personnes Ouest VI.
• Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et 
Clinique, Université catholique de Louvain, Brussels, Belgium. Comité d`Èthique Hospitalo-Facultaire.
• Centro Hospitalar do Porto, Portugal. Comissao de ética para a Saude – CES do CHP.
• Servicio Cantabro de Salud, Hospital Universitario Marqués de Valdecilla, Santander, Spain. Comite ético 
de investigacion clinical de Cantabria. IDIVAL.
• Hospital Clinic I Provicia, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. Comité 
Ética de Investigación Clínica del Hospital Clínic de Barcelona. HOSPITAL CLíNIC DE BARCELONA.
• Katholieke Universiteit Leuven, Belgium. Commissie Medische Ethiek UZ KU Leuven /Onderzoek.
• Klinikum der Universitaet zu Koeln, Cologne, Germany. Geschaftsstelle Ethikkommission
• Medizinische Hochschule Hannover, Germany. Ethikkommission.
• Medical University Vienna, Vienna, Austria. Ethik Kommission. Borschkegasse.
• Servicio Andaluz de Salud, Hospital Universitario Reina Sofía Córdoba, Spain. Comité de Ética e la Investi-
gación de Centro de Granada (CEI – Granada).
• Servicio Andaluz de Salud, Complejo hospitalario Universitario de Granada (Hospital Universitario San 
Cecilio), Spain. Comité de Ética e la Investigación de Centro de Granada (CEI – Granada).
• Servicio Andaluz de Salud, Complejo hospitalario Universitario de Granada (Hospital Virgen de las Nieves), 
Spain. Comité de Ética e la Investigación de Centro de Granada (CEI – Granada).
• Servicio Andaluz de Salud, Hospital Regional Universitario de Málaga, Spain. Comité de Ética e la Investi-
gación de Centro de Granada (CEI – Granada).
• Università degli studi di Milano, Milan, Italy. Policlinico di Milano, Comitato Etico Italy.
• Hospitaux Universitaires de Genève, Switzerland. DEAS –Commission Cantonale d`´ethique de la recherche 
Hopitaux universitaires de Geneve.
• University of Szeged, Szeged, Hungary. Csongrad Megyei Kormanyhivatal.
• Charite, Berlin, Germany. Ethikkommission.
• Andalusian Public Health System Biobank, Granada, Spain.
• Comité de Ética e la Investigación de Centro de Granada (CEI – Granada).
All patients recruited to the study were aged 18 years or older and signed an informed consent form, and 
all methods were carried out in accordance with relevant guidelines and regulations. The study adhered to the 
standards set by International Conference on Harmonization and Good Clinical Practice, and to the ethical 
principles that have their origin in the Declaration of Helsinki (2013). The protection of the confidentiality of 
records that could identify the included individuals is ensured as defined by the EU Directive 2001/20/EC and 
the applicable national and international requirements relating to data protection in each participating country.
The immunophenotyping of the individuals were performed by flow cytometry using 2 DuraClone antibody 
panels (Beckman Coulter) dedicated to the analysis of various populations of leukocytes and mononuclear cells in 
the peripheral blood of individuals (Supplementary Table 1). Absolute numbers using Flow Count fluorospheres 
(Beckman Coulter), frequencies of the different cell populations and MFIs of the cell surface markers were 
collected: CD3+CD19- T cells, CD3+CD4+CD8- T cells, CD3+CD4-CD8+ T cells, CD3-CD19+ B cells, CD3-
CD56+ NK cells, CD3-CD56highCD16low NK cells, CD3-CD56lowCD16high NK cells CD3+ CD56+ NK-like T 
6Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:11567  | https://doi.org/10.1038/s41598-020-68468-3
www.nature.com/scientificreports/
cells, CD4lowCD14+CD16- classic monocytes, CD4lowCD14+ CD16+ intermediate monocytes, CD4lowCD14-
CD16+ non-classic monocytes, CD15+CD16low eosinophils, and CD15+CD16high neutrophils with panel 1 
(Supplementary Figure 3c); HLA-DR-CD123+ basophils, HLA-DR+Lin-CD123+ CD11c- pDC, HLA-DR+ Lin-
CD123-CD11c+ mDC, HLA-DR+ Lin-CD123-CD11c+ CD1c+CD141- mDC1 and HLA-DR+Lin-CD123-
CD11c+CD1c-CD141+ mDC2 with panel 2 (Supplementary Figure 3d).
Furthermore, to reduce the variability that may occur during the sample preparations, all centers received 
the same SOP explaining how to prepare the lysis buffer, to handle the required volume of blood samples and 
rehydrate the antibodies in the DuraClone tubes, to add FlowCount fluorospheres (Beckman Coulter) for the 
absolute number calculation and finally how to prepare the instruments on a daily basis with the acquisition of 
Rainbow 8-peak beads (Beckman Coulter). These standardize procedure have been followed by all users in all 
centers to minimize technical bias.
Flow cytometry acquisition was managed at each center after a multi-center harmonization of flow cytometers 
to ensure mirroring of all instruments, thereby allowing subsequent integration of all the data obtained across the 
different sites and instruments, as previously  described12. Briefly, one flow cytometer (NAVIOS-1) was chosen as 
reference instrument and fixed the mean fluorescence intensities (MFIs) of 8 different fluorochrome conjugated 
antibodies using VersaComp Ab capture beads (Beckman Coulter). The ten other instruments adjusted their own 
PMT voltages to reach the same MFIs. These values constituted their initial reference settings. Furthermore, to 
evaluate the fluctuation of the instruments overtime and to minimize deviation, this standardization procedure 
was repeated every 3 to 6 months. If required, PMT voltages were adjusted to maintain identical MFI values of 
the target fluorescence intensities. In that case, the PMT values were set in the 2 multiparameter panels serving 
as new intra-instrument reference assessments for the inclusion of future individual samples. Subsequently to 
the standardization of all instruments, each center used Rainbow 8-peak beads (Beckman Coulter) on a daily 
basis to follow the stability of their instrument overtime. The deviation of the MFI values of the peaks of every 
fluorochrome must be < 5% compared to the internal reference. In cases where instrument performance failed, 
while cleaning, de-gassing flow cell and laser delay were verified, PMT values were modified to adjust the posi-
tion of the fluorescence peaks in their initial positions. Revised PMTs were then reported in the 2 panels of the 
immunophenotyping. Compensation matrices that could be impacted were adjusted later during the analysis 
procedure.
Moreover, to facilitate the elaboration of the scripts able to read LMD files generated by Beckman Coulter 
instruments as well as FCS files generated by BD Biosciences instruments, all centers received SOPs before 
starting the inclusions of samples to generate consistent instrument files. These SOPs were dedicated to the 
preparation of the flow cytometers (namely the protocols for the Beckman Coulter instruments and the sheets 
for the BD instruments), including uniform specific name of the different parameters (forward scatter and side 
scatter settings, fluorochrome designation), identical stop count or time of acquisition, and uniform labelling of 
the LMD and FCS files. Despite all these precautions, errors have been detected for some files. The script codes 
have thus been modified and implemented to detect and correct these errors in order to avoid the exclusion of 
the corresponding samples from the overall analyses (Supplementary Documents).
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